Using both conventional laboratory clotting profile and thrombelastography, coagulation status was monitored intraoperatively during liver transplantation in the first 75 cases performed at the Austin Hospital between June 1988 and October 1992.
Liver disease is a major cause of acquired multifactorial coagulopathy. Factor deficiencies, dysfibrinogenaemia, enhanced fibrinolysis and thrombocytopenia may co-exist with varying degrees of disseminated intravascular coagulation i ,2. Liver transplant surgery may be complicated by massive blood loss with specific risk factors for surgical bleeding compounded by additional coagulopathies occurring during the operation itselfl.4. This report documents the changes in coagulation parameters on both laboratory measurement and thrombelastography (TEG) during liver transplantation in a recently established liver transplant unit. Our aim was to identify patterns of coagulopathy and to evaluate the role of thrombelastography in clinical management of these clotting disturbances.
MATERIALS AND METHODS
The first 75 cases of liver transplantation performed on 71 patients at the Austin Hospital between June 1988 and October 1992 were studied. The patient details and surgical techniques have been described elsewhere l • At times 1+60 (min), 1+120, II + 30, III -5, III + 5, III + 30, III + 60 and III + 120 blood, samples were taken for estimation of platelet count, full clotting profile and thrombelastography (TEG). Full clotting profile included international normalized ratio for prothrombin (lNR), activated partial thromboplastin time (aPTT), fibrinogen, D-DIMER, and euglobulin clot lysis time (ECLT).
Thrombelastography is a technique first developed by Hartert in 1948 6 • It had little clinical Use for many years until it was re-evaluated in the surgical setting in 1974 7 • Subsequently it was further developed 8 , and has been more recently applied in both liver transplantation' and cardiac surgery9. The TEG involves two mechanical parts, a cuvette and a piston. Freshly drawn blood (0.36 ml) is placed in the cuvette which oscillates through 4 °45' at 37°C. The piston is suspended in the blood sample by a torsion wire which is transduced to a chart recorder. When no clot exists, the motion of the cuvette does not affect the piston and the chart records a straight line. As strands of fibrin form they attach to the piston and it becomes coupled to the motion of the cuvette. Hence the shearing elasticity of the evolving blood clot is transmitted to the thermal paper ( Figure 1 ).
The TEG pattern has component variables which are shown in Figure 2 . Reaction time (r) is the interval between the start of recording and the time at which the amplitude of the tracing is 2 mm. It reflects function of the intrinsic clotting pathway. Coagulation time (r + K) is the time required for the amplitude to reach 20 mm and gives information about not only intrinsic factors but also platelets and fibrinogen, which are also represented by the clot formation rate (Cl 0). Maximum amplitude (MA) is the largest amplitude on the thrombelastogram and is a measure of clot strength and elasticity, again reflecting the properties of platelets and fibrinogen as well as factor XIII. Whole blood clot lysis index (WBCLI) is the amplitude 60 minutes after MA is achieved (A60) as a percentage of MA and it denotes the amount of clot retraction or lysis'o. Thrombelastography is essentially a method of displaying the formation (thrombosis) and breakdown (fibrinolysis) of a whole blood clot and as such provides a visual pattern of functional clotting status ( Figure 3 ). TEG is now available in a computerized form which provides a visual display of the tracing with both observed and normal values. The baseline values (I + 60) for all laboratory parameters and TEG variables were compared with the values at the other times using the non-parametric Mann-Whitney test. Table 1 shows the intraoperative changes in laboratory coagulation parameters during the dissection (1 + 60, 1 + 120), anhepatic (1I + 30, III -5) and reperfusion (Ill + 5, III + 30, III + 60 and III + 120) stages for the 75 cases.
RESULTS
The platelet count was moderately low at the start of surgery and did not change significantly throughout the operation (Figure 4 ). The baseline values of INR and aPTT were abnormally prolonged. During the early dissection phase both decreased slightly. Subsequently there was a significant increase during the an hepatic and reperfusion periods. In particular there was a dramatic prolongation of aPTT with reperfusion The fibrinogen and D-DIMER levels at the start of surgery were in the normal range, as was the euglobulin clot lysis time (ECLT). In the anhepatic stage there was evidence of fibrinolysis as fibrinogen and ECLT decreased and D-DIMER increased. These changes were statistically significant (P<O.OI) and persisted during reperfusion. Fibrinogen level was lowest five minutes post reperfusion (III + 5), then slowly increased. D-DIMER elevation was maximal at III + 30 and then gradually declined. However both fibrinogen decrease and D-DIMER increase remained significantly altered (P<O.Ol) at III+120 when compared with baseline. In contrast the lowest values for ECLT were immediately before and immediately after reperfusion (P<O.OI), then rapid recovery to values which were
Stage and time significantly greater at III + 120 (P< 0.01) than the normal times recorded at baseline 1+60. These changes are summarized graphically in Figure 5 . Table 2 shows the intraoperative changes in thrombelastographic variables. The units for reaction time (r) and coagulation time (r + K) are expressed in mm rather than minutes as this is currently how they are displayed on computer-TEG (CTEG). The paper speed is standardized at 2 mm per minute. The reaction time was normal at baseline but then became significantly reduced during the late dissection and early anhepatic stages (P<O.01). With reperfusion there was a dramatic and significant (P< 0.01) change in the opposite direction as "r" time became markedly prolonged. Subsequently there was a gradual improvement although it remained abnormal at III + 120. Coagulation time showed the same trend with shortening during stages I and 11 followed by marked prolongation at reperfusion (P< 0.01) and subsequent partial recovery. The major changes in clot formation rate and maximum amplitude also occurred on graft reperfusion. Clot formation rate (ex 0) was in the normal range until it diminished significantly at III + 5 then partially recovered. MA was slightly less than normal from baseline until reperfusion when it narrowed (P < 0.01) and then progressively improved. Whole blood clot lysis index (WBCLI) was slightly reduced initially, then fell further during late anhepatic and early reperfusion stages (P< 0.01). It then recovered to normal rapidly (IlI+30) and remained significantly higher (P<O.01) than both its nadir at III + 5 and its baseline at 1+60 ( Figure 6 ).
DISCUSSION
The platelet count tended to be low at the start of surgery. Thrombocytopenia is a common feature of severe liver disease and may be due to inadequate marrow production, sequestration from hypersplenism, or consumption in low grades of disseminated intravascular coagulation'. The slight fall in platelet count intraoperatively was neither statistically nor clinically significant. One group of investigators has shown that platelets are sequestered in the liver graft immediately post reperfusion, but this is transient and subsequently splenic deposition contributes to postoperative thrombocytopenia l !.". Platelet function may also be disturbed intraoperatively with evidence of abnormal platelet aggregation occuring at reperfusion 'l • However the need for platelet transfusion in liver transplantation has been questioned by one group who reported no requirement for platelets (or cryoprecipitate) in 140 transplants with an overall survival of 87.5070 and no deaths from perioperative haemorrhagic compli- cationsl4. Their strategy was based on correction of functional platelet defects by administration of aprotinin. We used donor platelets sparingly in that they were not given in 570/0 of cases'. Moderate to severe thrombocytopenia and/or low maximum amplitude on TEG were not treated in the absence of a bleeding diathesis. There were essentially three demonstrable changes in coagulation in this study. Firstly from a baseline of prolonged aPTT and INR (reflecting factor deficiencies) but normal rand r + k on TEG (implying adequate clotting factor activity), all of these indices shortened in the early stage of the surgery. This is probably attributable to the hypercoagulability component of the acute phase response to a surgical stimulus, and is more a typical reaction to surgery rather than a specific effect in liver transplantation. It is transient and of no importance. The second and third events are fibrinolysis and reperfusion coagulopathy. They are however definite sequelae of orthotopic liver transplantation, but are also transient and probably important only in certain clinical circumstances.
Our results indicate that low-grade fibrinolysis probably exists preoperatively. Then during the anhepatic stage fibrinolytic activity increases, becoming most pronounced immediately before and immediately after reperfusion. Subsequent recovery is rapid with ECLT and WBCLI normal within 30 minutes, although fibrinogen increase and D-DIMER decrease proceed more slowly. This pattern of fibrinolysis has been confirmed by many different investigators ls . 19 .
The likely aetiology is that inadequate or totally absent liver function results in increased levels of tissue plasminogen activator (t-PA), minimal levels of plasminogen activator inhibitor (PAl) and sometimes also reduced levels of a2-antiplasmin (a2_AP)16.18.2o.21. PAl and a2-AP require a functioning liver for their synthesis and t-PA is normally metabolized by hepatic clearance. An alternative mechanism for elevated t-PA is increased release from damaged endothelium (e.g. donor liver) and this may partly explain the immediate post reperfusion fibrinolysis '6 • However good evidence that the major reason for increased tPA is hepatic clearance failure comes from a study demonstrating high t-PA levels in orthotopic liver transplantation but normal levels in auxiliary (heterotopic) liver transplantation 22 • Activation of protein C has also been implicated'. The popular opinion is that this process of fibrinolysis is a primary event. However it is possible that fibrinolysis occurring secondary to a consumptive coagulopathy may also contribute. Several groups have found increased formation of thrombin-antithrombin (TAT) complexes during liver transplantation especially after reperfusion 18.22.23.
Approaches to the management of fibrinolysis during liver transplantation vary. Recently some centres have recommended prophylactic aprotinin administration with claims of reduced blood product requirement 24 ,25. Others have evaluated the role of the more specific anti-fibrinolytics tranexamic acid and epsilon aminocaproic acid (~-ACA). Neither of these agents has been found to reduce bleeding when given prophylactic-ally26,27, however epsilon aminocaproic acid has been shown to reverse severe fibrinolysis and bleeding when used in association with thrombelastographic monitoring 28 • It is our view that the fibrinolysis which accompanies orthotopic liver transplantation is predictable, self-limited and requires no intervention unless there is a problem with a bleeding diathesis clinically and the TEG confirms fibrinolysis. We used ~-ACA on only six occasions when bleeding was severe and there was demonstrable fibrinolysis. Some recent evidence suggests that very low levels of Ci2-antiplasmin may correlate with a significant risk of bleeding due to accelerated fibrinolysis 29 , so perhaps there may be a role for prophylactic anti-fibrinolytics in appropriately screened patients.
The dramatic prolongation of aPTT, reaction and coagulation times as well as reduced clot formation rate and MA which are seen on reperfusion imply that in addition to fibrinolysis a multifactorial coagulopathy occurs. Evidence for a consumptive process has already been mentioned as well as abnormal platelet aggregation iJ ,18,22,21. The presence of thrombin-antithrombin (TAT) complexes in systemic blood after reperfusion has been found to be associated with the presence of a variety of substances including the cytokine tumour necrosis factor '0 , the phagocyte proteinases such as cathepsin B'\ and thrombomodulin'2. Dilution of clotting factors is also responsible. Assays of clotting factors during liver transplantation show that there is a progressive fall in all factors with the nadir soon after reperfusion and then subsequent recovery to baseline by the end of the operation. The initial decline is explained by a combination of relative dilution depending on the speed and adequacy of replacement therapy, reduced or absent synthesis and disappearance via either a consumptive process or degradation by active plasmin (especially of factors I, V, and VIII) 15 . The additional dilution component post reperfusion occurs as the recently flushed donor liver is incorporated into the circulation. A heparin effect has been demonstrated after reperfusion JJ ,J4 and is thought to be due to release of either sequestered heparin administered to the donor or a heparin-like substance released from donor endothelium. Its effect however is minimal. Finally the metabolic, biochemical and physiological sequelae of reperfusion may impair coagulation. Pre-vention of hypothermia, hypocalcaemia, acidosis and hypoperfusion are basic tenets of clinical management.
In the usual circumstance with uncomplicated surgery, this reperfusion coagulopathy represents a manifestation of "normal" graft ischaemia and reperfusion and is not a clinical problem. Its resolution provides one of several indices of improving graft function.
Thrombelastography (TEG) has become a common adjunct in the management of coagulation during liver transplantation. The TEG is basically a modified whole blood clotting time and as such provides on-site analysis of global coagulation and fibrinolysis. Information is available much more rapidly (15 minutes) than laboratory coagulation results (45 minutes). In addition to the data obtained from the native blood sample the development of in vitro tests against various agents has further increased the utility of the TEG'°. For example, using a simultaneous native and in vitro E-ACA test, a diagnosis of fibrinolysis likely to respond to specific treatment is available within minutes.
Correlation between TEG variables and laboratory coagulation parameters is inconsistent 7,8,9, but as has been noted this is not surprising, given that the TEG variables are interdependent, measuring the interaction of the coagulation cascade and platelets in whole blood rather than specific end-points in centrifuged plasma samples'5. In fact the global yet overlapping data that is provided in a thrombelastogram allows the clinician to sequentially target replacement therapy and/or drug treatment. Importantly also the recognition of an "acceptable" rather than absolutely normal trace allows the clinician to withhold unnecessary intervention.
In addition to its contribution to management of coagulation during liver transplantation, we have found the TEG extremely useful as a liver function test. In particular the period after reperfusion is when evidence of adequate graft function is eagerly sought, and rapid restoration of a normal TEG almost certainly indicates that to be the case. Conversely a poor thrombelastogram 60 minutes post reperfusion may indicate the need to surgically reassess graft blood flow.
In conclusion, orthotopic liver transplantation involves a predictable pattern of coagulation disturbance. The predominant feature is fibrinolysis which is essentially self-limited and usually requires no treatment. Major bleeding sometimes occurs but this is mostly due to surgical factors. If massive transfusion is required then the contribution to bleeding from coagulopathic causes is more likely and appropriate replacement and/or drug therapy should be guided by thrombelastography and assessment of clinical bleeding diathesis.
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